Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson's disease.
D005406:Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide / Q000494:pharmacology; D001921:Brain / Q000378:metabolism; D002230:Carbidopa / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D015103:Droxidopa / Q000378:metabolism / Q000627:therapeutic use*; D007980:Levodopa / Q000494:pharmacology; D008125:Locus Coeruleus / Q000378:metabolism / Q000473:pathology; D009206:Myocardium / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism*; D010293:Pargyline / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy*; D012694:Serine / Q000031:analogs & derivatives*; D013237:Stereoisomerism; D014443:Tyrosine / Q000378:metabolism
D005406:Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; D014443:Tyrosine; D012694:Serine; D007980:Levodopa; D010293:Pargyline; D015103:Droxidopa; D002230:Carbidopa; D004298:Dopamine; D009638:Norepinephrine